Reuters
Shire CEO Flemming OrnskovG
- Takeda has reached a deal to buy Adderall drugmaker Shire for $64.3 billion.
- The deal comes after a handful of rejections from Shire and a short-lived potential for a bidding war between Takeda and Botox-maker Allergan.
- The two companies each have a phalanx of investment bankers advising on the possible transaction, with four of the big five Wall Street banks landing a role.
Takeda has reached a preliminary agreement to buy Adderall drugmaker Shire for $64 billion in the largest pharma deal of the year.
Takeda first approached Shire in March, and Shire had rejected four of the company's earlier bids. Takeda's pursuit of Shire heated up further last week when Botox-maker Allergan revealed it was weighing an offer for the company.
Shire has long been a takeover target. US drugmaker AbbVie nearly acquired the company in 2014, but the deal collapsed due to changes in US tax law.
The two companies each have a phalanx of investment bankers advising on the potential transaction. Here's what you need to know about them:
Shire
Shire's getting advice from Goldman Sachs, Morgan Stanley, and Citigroup.
Citigroup
The Citi team is made up of Chris Hite, Cary Kochman, Jan Skarbek and Andrew Seaton. Hite is global head of healthcare investment banking at the US bank, Kochman is the Chicago-based cohead of global mergers and acquisitions, and Skarbek is a veteran UK banker who, like Goldman's Harper, is also working on the Klépierre- Hammerson deal talks. Seaton meanwhile is a UK corporate broking specialist.
Goldman Sachs
Goldman Sachs' team is made up of Anthony Gutman, Robert King, and Nick Harper. Gutman has long been a UK dealmaking kingpin for Goldman Sachs. In the past 12 months, he's advised the likes of Spire Healthcare, Worldpay, and Amec Foster Wheeler. King is a healthcare banking veteran, while Harper is a seasoned UK dealmaker who's also been working on Klépierre's bid for Hammerson right now.
Morgan Stanley
The Morgan Stanley team is up of Clint Gartin, Philippe Gallone, David Kitterick and Peter Moorhouse. US-based Gartin is a veteran healthcare banker who's now chairman of investment banking at Morgan Stanley. He's worked on more than $1 trillion of merger and acquisition transactions, according to a conference bio. Gallone is a senior figure in the European healthcare practice at Morgan Stanley, while Kitterick is a lawyer-turned-banker based in London. Moorhouse is a UK corporate broking veteran.
Takeda
Takeda's taking advice from Evercore, JPMorgan and Nomura
Evercore
Evercore's team is made up of Will Hiltz, John Honts, and Julian Oakley. Hiltz is a New York-based senior managing director and head of the firm's general advisory group. He's advised on a wide range of transactions in the past, ranging from working for CVS Health on its $13 billion acquisition of Omnicare, to advising Broadcom on its $37 billion sale to Avago Technologies. Honts is a healthcare specialist in New York who's worked on deals for CVS, Wyeth, and Sanofi Aventis. And Oakley is a London-based senior managing director.
JPMorgan
JPMorgan's team is made up Michele Colocci, Dwayne Lysaght, James Mitford. A healthcare specialist, Colocci is a recent hire to JPMorgan, rejoining last year from Morgan Stanley as cohead of industry coverage in Europe. Lysaght is a UK takeover specialist, while Mitford is a UK-based healthcare specialist.
Nomura
Nomura's team is made up of Akira Kiyota, Paolo Cicchine, Andrew McNaught, and Oliver Tucker. The Japanese bank has long been an adviser to Takeda, with Cicchine involved in the company's 2011 takeover of Nycomed.